 Proto-Oncogene Proteins c-kit
"Proto-Oncogene Proteins c-kit" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A protein-tyrosine kinase receptor that is specific for STEM CELL FACTOR. This interaction is crucial for the development of hematopoietic, gonadal, and pigment stem cells. Genetic mutations that disrupt the expression of PROTO-ONCOGENE PROTEINS C-KIT are associated with PIEBALDISM, while overexpression or constitutive activation of the c-kit protein-tyrosine kinase is associated with tumorigenesis.
| Descriptor ID |
D019009
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.400.050 D12.776.543.750.060.124 D12.776.543.750.705.852.150.100 D12.776.543.750.750.400.200.170 D12.776.624.664.700.183 D23.050.301.264.035.590 D23.101.100.110.590
|
| Concept/Terms |
Proto-Oncogene Proteins c-kit- Proto-Oncogene Proteins c-kit
- Proto Oncogene Proteins c kit
- c-kit, Proto-Oncogene Proteins
- c-kit Protein
- c kit Protein
- c-kit Receptor
- c kit Receptor
- CD117 Antigen
- CD117 Antigens
- kit Proto-Oncogene Protein
- Proto-Oncogene Protein, kit
- kit Proto Oncogene Protein
- p145 c-kit
- c-kit, p145
- p145 c kit
- p145(c-kit)
- p145c-kit
- p145c kit
- Proto-Oncogene Protein c-kit
- Proto Oncogene Protein c kit
- c-kit, Proto-Oncogene Protein
- Proto-Oncogene Protein kit
- Proto Oncogene Protein kit
- Receptor, Stem Cell Factor
- SCF Receptor
- Stem Cell Factor Receptor
- Antigens, CD117
|
Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins c-kit".
- Chemicals and Drugs [D]
- Enzymes and Coenzymes [D08]
- Enzymes [D08.811]
- Transferases [D08.811.913]
- Phosphotransferases [D08.811.913.696]
- Phosphotransferases (Alcohol Group Acceptor) [D08.811.913.696.620]
- Protein Kinases [D08.811.913.696.620.682]
- Protein-Tyrosine Kinases [D08.811.913.696.620.682.725]
- Receptor Protein-Tyrosine Kinases [D08.811.913.696.620.682.725.400]
- Proto-Oncogene Proteins c-kit [D08.811.913.696.620.682.725.400.050]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptor Protein-Tyrosine Kinases [D12.776.543.750.060]
- Proto-Oncogene Proteins c-kit [D12.776.543.750.060.124]
- Receptors, Immunologic [D12.776.543.750.705]
- Receptors, Cytokine [D12.776.543.750.705.852]
- Receptors, Colony-Stimulating Factor [D12.776.543.750.705.852.150]
- Proto-Oncogene Proteins c-kit [D12.776.543.750.705.852.150.100]
- Receptors, Peptide [D12.776.543.750.750]
- Receptors, Growth Factor [D12.776.543.750.750.400]
- Receptors, Colony-Stimulating Factor [D12.776.543.750.750.400.200]
- Proto-Oncogene Proteins c-kit [D12.776.543.750.750.400.200.170]
- Neoplasm Proteins [D12.776.624]
- Oncogene Proteins [D12.776.624.664]
- Proto-Oncogene Proteins [D12.776.624.664.700]
- Proto-Oncogene Proteins c-kit [D12.776.624.664.700.183]
- Biological Factors [D23]
- Antigens [D23.050]
- Antigens, Surface [D23.050.301]
- Antigens, Differentiation [D23.050.301.264]
- Antigens, CD [D23.050.301.264.035]
- Proto-Oncogene Proteins c-kit [D23.050.301.264.035.590]
- Biological Markers [D23.101]
- Antigens, Differentiation [D23.101.100]
- Antigens, CD [D23.101.100.110]
- Proto-Oncogene Proteins c-kit [D23.101.100.110.590]
Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins c-kit".
This graph shows the total number of publications written about "Proto-Oncogene Proteins c-kit" by people in this website by year, and whether "Proto-Oncogene Proteins c-kit" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 | | 1997 | 1 | 0 | 1 | | 1998 | 2 | 0 | 2 | | 1999 | 1 | 1 | 2 | | 2000 | 1 | 0 | 1 | | 2001 | 0 | 1 | 1 | | 2002 | 1 | 1 | 2 | | 2003 | 4 | 4 | 8 | | 2004 | 3 | 0 | 3 | | 2005 | 2 | 0 | 2 | | 2006 | 2 | 1 | 3 | | 2007 | 0 | 5 | 5 | | 2008 | 1 | 1 | 2 | | 2009 | 0 | 2 | 2 | | 2011 | 0 | 5 | 5 | | 2012 | 1 | 1 | 2 | | 2013 | 1 | 2 | 3 | | 2014 | 4 | 1 | 5 | | 2015 | 2 | 1 | 3 | | 2016 | 0 | 1 | 1 | | 2017 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Proto-Oncogene Proteins c-kit" by people in Profiles.
-
Dias-Santagata D, Selim MA, Su Y, Peng Y, Vollmer R, Chlopik A, Tell-Marti G, Paral KM, Shalin SC, Shea CR, Puig S, Fernandez-Figueras MT, Biernat W, Rys J, Marszalek A, Hoang MP. KIT mutations and CD117 overexpression are markers of better progression-free survival in vulvar melanomas. Br J Dermatol. 2017 Nov; 177(5):1376-1384.
-
Chillo O, Kleinert EC, Lautz T, Lasch M, Pagel JI, Heun Y, Troidl K, Fischer S, Caballero-Martinez A, Mauer A, Kurz ARM, Assmann G, Rehberg M, Kanse SM, Nieswandt B, Walzog B, Reichel CA, Mannell H, Preissner KT, Deindl E. Perivascular Mast Cells Govern Shear Stress-Induced Arteriogenesis by Orchestrating Leukocyte Function. Cell Rep. 2016 08 23; 16(8):2197-2207.
-
Wong SJ, Karrison T, Hayes DN, Kies MS, Cullen KJ, Tanvetyanon T, Argiris A, Takebe N, Lim D, Saba NF, Worden FP, Gilbert J, Lenz HJ, Razak AR, Roberts JD, Vokes EE, Cohen EE. Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors. Ann Oncol. 2016 Feb; 27(2):318-23.
-
Chisholm KM, Merker JD, Gotlib JR, Gitana G, Lefterova M, Zehnder JL, George TI, Arber DA, Ohgami RS. Mast cells in systemic mastocytosis have distinctly brighter CD45 expression by flow cytometry. Am J Clin Pathol. 2015 Apr; 143(4):527-34.
-
Carvajal RD, Lawrence DP, Weber JS, Gajewski TF, Gonzalez R, Lutzky J, O'Day SJ, Hamid O, Wolchok JD, Chapman PB, Sullivan RJ, Teitcher JB, Ramaiya N, Giobbie-Hurder A, Antonescu CR, Heinrich MC, Bastian BC, Corless CL, Fletcher JA, Hodi FS. Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition. Clin Cancer Res. 2015 May 15; 21(10):2289-96.
-
Zukotynski K, Yap JT, Giobbie-Hurder A, Weber J, Gonzalez R, Gajewski TF, O'Day S, Kim K, Hodi FS, Van den Abbeele AD. Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma. Cancer Imaging. 2014 Nov 12; 14:30.
-
Cherenfant J, Talamonti MS, Hall CR, Thurow TA, Gage MK, Stocker SJ, Lapin B, Wang E, Silverstein JC, Mangold K, Odeleye M, Kaul KL, Lamzabi I, Gattuso P, Winchester DJ, Marsh RW, Roggin KK, Bentrem DJ, Baker MS, Prinz RA. Comparison of tumor markers for predicting outcomes after resection of nonfunctioning pancreatic neuroendocrine tumors. Surgery. 2014 Dec; 156(6):1504-10; discussion 1510-1.
-
Yun EJ, Baek ST, Xie D, Tseng SF, Dobin T, Hernandez E, Zhou J, Zhang L, Yang J, Sun H, Xiao G, He D, Kittler R, Hsieh JT. DAB2IP regulates cancer stem cell phenotypes through modulating stem cell factor receptor and ZEB1. Oncogene. 2015 May 21; 34(21):2741-52.
-
Ohgami RS, Chisholm KM, Ma L, Arber DA. E-cadherin is a specific marker for erythroid differentiation and has utility, in combination with CD117 and CD34, for enumerating myeloblasts in hematopoietic neoplasms. Am J Clin Pathol. 2014 May; 141(5):656-64.
-
Leung KK, Hause RJ, Barkinge JL, Ciaccio MF, Chuu CP, Jones RB. Enhanced prediction of Src homology 2 (SH2) domain binding potentials using a fluorescence polarization-derived c-Met, c-Kit, ErbB, and androgen receptor interactome. Mol Cell Proteomics. 2014 Jul; 13(7):1705-23.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|